Peyronie's Disease (Extended Investigational Adjunct)
Highly investigational extended-protocol adjunct for stable Peyronie's disease; case reports only; collagenase clostridium histolyticum and surgical correction remain primary.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for Peyronie's disease. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational extended-protocol, with case reports only, and only in stable-phase disease.
- What evidence exists?
- Tier C (investigational). Only isolated case reports describe modest plaque-area or curvature reduction after stable-phase hirudotherapy. There are no controlled trials. Per AUA 2015 guideline (reaffirmed), evidence-based management of Peyronie's disease includes oral pentoxifylline (modest evidence), intralesional collagenase clostridium histolyticum (FDA-approved 2013), intralesional interferon or verapamil, and surgical correction (plication, plaque incision/excision with grafting, or prosthesis for concurrent ED). The acute (inflammatory) phase is treated differently from the stable phase. Direct genital placement carries significant risk and is performed only by experienced operators in highly selected patients.
- Main risks
- Bleeding from bite sites that may be substantial given penile vascularity
- Painful penile hematoma or bruising lasting 1 to 3 weeks
- Local skin infection or Aeromonas infection at a genital site
- Allergic reaction to leech saliva
- Worsening of plaque-related curvature or new fibrosis at the bite site
- Erectile dysfunction from local trauma or pressure
- Pain during erections after the procedure
- Delay of evidence-based intralesional collagenase or surgical correction
- Who should not consider this
- Anyone in the acute (inflammatory) phase of Peyronie's disease
- Patients with severe curvature compromising intercourse (surgical correction preferred)
- Patients with erectile dysfunction requiring a penile prosthesis
- Patients within 8 weeks of intralesional therapy
- Patients with active genital infection, balanitis, or skin breakdown
- Patients on anticoagulants or with bleeding disorders
- Patients offered placement at the glans, frenulum, or urethral meatus (these sites are absolutely contraindicated)
- What to ask your clinician
- Is my disease in the stable phase (at least 12 months from acute onset)?
- Have I been offered intralesional collagenase clostridium histolyticum (FDA-approved 2013)?
- Have surgical options (plication, plaque incision/excision with grafting, prosthesis) been considered?
- What is the practitioner's specific experience with hirudotherapy in Peyronie's, including outcomes and complications?
- Where exactly will the leech be placed — confirm it is the shaft only, never glans, frenulum, or urethra?
- What is the post-procedure compression and infection-prevention plan?
- When to seek urgent care
- Inability to maintain or achieve erection after the procedure
- Severe penile pain not improving with rest and analgesics
- Visible blood in urine or bleeding from the urethra
- Spreading redness, warmth, pus, or red streaks at any bite site
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Sudden worsening of curvature or new plaque-like firmness
What this does NOT mean
- It does not replace intralesional collagenase or surgical correction, which have FDA-cleared or evidence-based status.
- It is not appropriate during the acute (inflammatory) phase of Peyronie's disease.
- It is not placed at the glans, frenulum, or urethral meatus.
- Only case reports exist; expected benefit is modest and not well characterized.
Safety cross-references
Clinical Profile
- Category
- urogenital
- ICD-10
- N48.6
- Safety tier
- high
Evidence Summary
Peyronie's disease management per the AUA 2015 guideline (reaffirmed) includes oral pentoxifylline (modest evidence), intralesional collagenase clostridium histolyticum (FDA-approved 2013), intralesional interferon or verapamil, and surgical correction (plication, plaque incision/excision with grafting, prosthesis). No controlled clinical trial of leech therapy for Peyronie's disease has been published; use is investigational and mechanistic only, and the honest evidence grade is D. Any antifibrotic rationale for leech salivary peptides is theoretical, and direct genital placement carries significant risks, so this remains an unproven extended-protocol consideration distinct from the standard Peyronie's entry.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Khandelwal R et al. (2019)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Acute-phase Peyronie's (inflammation present)
- Erectile dysfunction requiring prosthesis (surgical solution)
- Severe curvature compromising intercourse (surgical preferred)
- Recent intralesional therapy (<8 weeks)
- Active genital infection or skin breakdown
Related Conditions
Peyronie's Disease (Stable Phase)
Investigational use for stable-phase Peyronie's disease; case-report-level evidence only. Standard treatments (verapamil, collagenase, surgery) remain first-line.
Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)
Investigational use for category III CP/CPPS; small case series suggest symptom reduction. Multimodal therapy remains standard.
Chronic Prostatitis / Chronic Pelvic Pain Syndrome (Extended Protocol)
Investigational extended-protocol adjunct for NIH Category III chronic prostatitis/CPPS; small case series only; UPOINT-directed therapy remains primary.
Interstitial Cystitis / Bladder Pain Syndrome (Investigational)
Highly investigational adjunct for IC/BPS refractory to conventional therapy; case reports only; AUA-guideline stepwise therapy remains primary.